LABETALOL HYDROCHLORIDE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for labetalol hydrochloride and what is the scope of patent protection?

Labetalol hydrochloride is the generic ingredient in five branded drugs marketed by Apothecon, Baxter Hlthcare Corp, Caplin, Gland Pharma Ltd, Hikma, Hospira, Rising, Steriscience, Schering, Sebela Ireland Ltd, Andas 5 Holding, Appco, Cadila Pharms Ltd, Endo Operations, Epic Pharma Llc, Eywa, Heritage Pharma, Rubicon, Sandoz, Teva, Unichem, Watson Labs, Zydus Pharms, and Alvogen, and is included in thirty NDAs. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for labetalol hydrochloride. Thirty-nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LABETALOL HYDROCHLORIDE

US Patents:	0
Tradenames:	5
Applicants:	24
NDAs:	30
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	39
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	69
Patent Applications:	1,157
What excipients (inactive ingredients) are in LABETALOL HYDROCHLORIDE?	LABETALOL HYDROCHLORIDE excipients list
DailyMed Link:	LABETALOL HYDROCHLORIDE at DailyMed

Recent Clinical Trials for LABETALOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boston Medical Center	Phase 4
Marshall University	Phase 2
Loma Linda University	N/A

See all LABETALOL HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for LABETALOL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	5MG/ML	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LABETALOL HYDROCHLORIDE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for LABETALOL HYDROCHLORIDE

Adrenergic alpha-1 Receptor Antagonists
Adrenergic beta-Antagonists
Antihypertensive Agents
Sympathomimetics

Anatomical Therapeutic Chemical (ATC) Classes for LABETALOL HYDROCHLORIDE

C07AG	Alpha and beta blocking agents
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for LABETALOL HYDROCHLORIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	SOLUTION;INTRAVENOUS	213330-005	Mar 18, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Hikma	LABETALOL HYDROCHLORIDE IN DEXTROSE	labetalol hydrochloride	SOLUTION;INTRAVENOUS	213330-001	Nov 9, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Endo Operations	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	200908-002	Jul 10, 2012	AB	RX	No	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Epic Pharma Llc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	212990-003	Sep 30, 2020	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Apothecon	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	075223-001	Nov 20, 1998		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Eywa	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	207863-003	Feb 4, 2019	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for LABETALOL HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sebela Ireland Ltd	TRANDATE	labetalol hydrochloride	INJECTABLE;INJECTION	019425-001	Dec 31, 1985	⤷ Sign Up	⤷ Sign Up
Schering	NORMODYNE	labetalol hydrochloride	TABLET;ORAL	018687-004	Aug 1, 1984	⤷ Sign Up	⤷ Sign Up
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-004	Aug 1, 1984	⤷ Sign Up	⤷ Sign Up
Schering	NORMODYNE	labetalol hydrochloride	INJECTABLE;INJECTION	018686-001	Aug 1, 1984	⤷ Sign Up	⤷ Sign Up
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-003	Aug 1, 1984	⤷ Sign Up	⤷ Sign Up
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-001	May 24, 1985	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.